FDA cited Vi-Jon for manufacturing-rule violations after finding microbial water contamination, leaks, weak investigations, and data-integrity failures in OTC drugs and cosmetics.
What happened
FDA inspected the drug manufacturing facility in St. Louis, MO, from October 4 to October 13, 2021. Investigators found water-system sampling was not representative and Burkholderia cepacia, a waterborne bacterium, had been found repeatedly in finished drug products; they also saw undocumented water leaks, inadequate cleaning and maintenance, incomplete investigations of failing test results and complaints, and laboratory computer controls that allowed shared administrative access and deletion of files. FDA also cited insanitary conditions for cosmetics.
What FDA found
FDA found the water-system sampling plan did not represent the whole system and did not adequately monitor or test for Burkholderia cepacia, a waterborne bacterium that had repeatedly contaminated finished drug products.
21 CFR 211.160(b)FDA found inadequate cleaning and maintenance procedures, including undocumented water leaks, a leaking raw-material valve, and rust in a laboratory hood.
21 CFR 211.67(b)FDA found failing test results and complaints were not thoroughly investigated, including Burkholderia cepacia contamination and missing or illegible lot codes.
21 CFR 211.192FDA found laboratory computer controls were inadequate because quality-unit users shared an administrative account and files had been deleted, and computer audit trails were not reviewed before batch release.
21 CFR 211.68(b)FDA found cosmetics were made under insanitary conditions, with stagnant water and leaking processing lines as potential sources of bacterial contamination.
section 601(c) of the FD&C Act, 21 U.S.C. 361(c)FDA said executive management failed to provide proper oversight and that the quality system was ineffective.
21 CFR parts 210 and 211
What FDA wants
FDA asks Vi-Jon to provide comprehensive corrective action plans, independent assessments, risk assessments, and remediation for the water system, investigations, data integrity, and quality-unit oversight, and strongly recommends a qualified CGMP consultant. The letter excerpt does not state a specific response deadline.
Who should pay attention
- OTC drug and cosmetic brands that use contract manufacturers
- companies buying hand sanitizers or personal-care products made at this site
- quality teams responsible for water systems, complaints, and laboratory data integrity
This is a summary. Read the original letter on fda.gov.